Celldex Therapeutics CLDX
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 99th percentile, 5-year average -12.4x
Around its usual level · 45th percentile, 5-year average 4.0x
#3953 of 5330 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 95th percentile, 5-year average 1,656.3x
#5144 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.49 | – | 4.04 | 45% (cheaper than usual) | #3953 of 5330 (1 = cheapest) |
| PE | -6.72 | -6.93 | -12.36 | 99% (pricier than usual) | – |
| PS | 14,331.99 | 1,000.38 | 1,656.30 | 95% (pricier than usual) | #5144 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on CLDX.
Sign in to join the discussion.